AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- 4D Medical is commercially using its XV LVAS™ technology for the first time in the United States.
- The pilot program will help open the door to the vast US diagnostics market.
- Respiratory diagnostics has an annual global industry size of US$31 billion.
Medical technology company 4DMedical Limited (ASX:4DX) has hit a major milestone as part of its quest to grow its global footprint. The company has started a clinical pilot program in the US. The first scans are underway at Providence St. Joseph Hospital in Orange, California.
The pilot program is expected to help open the door to the huge US diagnostics market.
XV Technology – unprecedented role in surveillance of lung function
4DX is a respiratory imaging technology company providing respiratory diagnostics for all lung disorders. The pilot program will use the company’s XV LVAS™ technology in the United States for the first time. It has already completed screening in various respiratory conditions, including chronic obstructive pulmonary disease (COPD) and long-COVID.
XV LVAS™ is a unique and transformative technology that can accurately and promptly scan lung functions as the patient breathes. It enables early diagnosis and the monitoring of changes over time. It is being considered as a life-changing technology for doctors, patients and community.
St. Joseph Hospital's successful scans rely on prior and concurrent usage of the technology in clinical trials at a few other sites across the US.
Image source: © 2022 Kalkine Media®, Data Source: 4DX update
Key milestone to expand 4D Medical's global footprint
In Australia, the company offers respiratory scans commercially through the I-MED Radiology Network, which is the largest provider of medical imaging in the country. The medical imaging provider adopted the company’s XV Technology™ after completing a clinical pilot program.
4DMedical is implementing a similar practice in the US.
Last month, 4D Medical launched its XV scanner, the first dedicated lung scanner in the world. The scanner integrates XV LVAS™ technology representing a remarkable step forward in lung diagnostics. It captures detailed maps of pulmonary function in less than 10 seconds and delivers less radiation than a single chest X-ray.
Related read: 4DMedical (ASX:4DX) shares surge over 21% on launching world’s first lung scanner
Stock information: At the time of writing this article, shares of 4DX were trading at AU$0.745 on 6 April 2022. The company has a market cap of AU$223.81 million.
Also read: ASX stocks in focus amid Australia’s record health budget
